Ben Scruggs, PhD


As part of the investment team, Ben supports new portfolio company diligence, existing portfolio strategy, and overall firm operations. He currently serves as CEO at Altis Biosystems. He also serves as Manager for L2 Ventures, a fund dedicated to UNC-Chapel Hill related start-ups. Previously, he led strategic initiatives at Tune Therapeutics. Prior to joining Hatteras in 2016, Ben completed a postdoctoral fellowship in the Epigenetics and Stem Cell Biology Laboratory at the National Institute of Environmental Health Sciences

Ben received a PhD in molecular cell biology from Washington University in St. Louis, with the support of an NIH/NHLBI fellowship. Ben also holds a B.E. in biomedical engineering from Vanderbilt University. He has performed research in the fields of genomics, metabolism, RNA biology, and transcriptional regulation. His research has been published in peer-reviewed journals including Molecular Cell and Cell Metabolism, among others.


Ben is a director on the boards of Altis Biosystems, IMMvention Therapeutix, and Veralox Therapeutics. He also serves as a board observer at Myeloid Therapeutics and Qpex Biopharma. Previously, Ben was involved with Dropworks (acquired in 2021, GrayBug Vision, and Rodin Therapeutics (acquired in 2019), among others.